10 Best New Penny Stocks to Invest In
On December 30, TipRanks reported that the Goldman Sachs portfolio strategy research team is optimistic about small-cap stocks heading into early 2026.
Neumora Therapeutics Inc. (NMRA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | MIC Capital Partners Mubadala Investment | 4,460,700 | $8,118,474 | 1.62% | |
| 2. | Siren L.L.C. Raymond Debbane | 4,358,283 | $7,932,075 | 0.31% | |
| 3. | Millennium Management Israel Englander | 2,008,248 | $3,655,011 | +64% | 0% |
| 4. | Tang Capital Management Kevin C. Tang | 1,400,000 | $2,548,000 | 0.1% | |
| 5. | Renaissance Technologies Jim Simons | 1,163,976 | $2,118,436 | -19% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.61 | 1,915,700 | $4,999,977.00 | 6,046,907 | 2025-10-27 | Filing | |
| $2.61 | 1,915,700 | $4,999,977.00 | 6,046,907 | 2025-10-27 | Filing | |
| $2.61 | 1,915,700 | $4,999,977.00 | 6,046,907 | 2025-10-27 | Filing | |
| $11.98 | 3,357 | $40,216.86 | 4,131,207 | 2023-11-14 | Filing | |
| $11.75 | 31,653 | $371,922.75 | 4,127,850 | 2023-11-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.68 | 114,703 | $307,025.52 | 0 | 2025-11-11 | Filing | |
| $1.69 | 13,871 | $23,468.34 | 7,405,004 | 2025-02-18 | Filing | |
| $1.69 | 1,978 | $3,350.53 | 22,470 | 2025-02-18 | Filing | |
| $1.68 | 8,565 | $14,347.23 | 88,935 | 2025-02-18 | Filing | |
| $1.67 | 5,614 | $9,383.24 | 309,092 | 2025-02-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 163,386 | $292,461 | 0.18% | |
| 2. | 19,000 | $34,010 | 0% | |
| 3. | 16,992 | $30,416 | 0% | |
| 4. | 1,466 | $2,624 | 0% | |
| 5. | 1,022 | $1,829 | 0% |
News See All
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the best stocks under $5 with highest upside potential. On October 28, Needham lifted its price target on Neumora Therapeutics, Inc.
14 Stocks Under $5 with Highest Upside Potential
On October 28, Paul Tudor Jones, Tudor Investment Corporation founder and CIO and Robin Hood Foundation founder and board member, appeared on CNBC’s 'Squawk Box' to talk about the latest trends in the...
Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861
Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the best IPO stocks to buy according to Wall Street analysts.
13 Best IPO Stocks to Buy According to Wall Street Analysts
On August 14, Tony Kim, Centerview Partners co-president, joined CNBC's 'Closing Bell: Overtime' to discuss the IPO market and the dealmaking environment.
Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. This is RG, your conference operator today. [Operator Instructions] Please be advised that today's conference is being recorded.
11 Best New Penny Stocks to Buy Right Now
On July 28, the Opening Bid team at Yahoo Finance and Victoria Fernandez, chief market strategist at Crossmark Global Investments, discussed the rise in cheap stock trading and what it can mean for the...
10 Hot Penny Stocks to Invest in Now
CNBC reported that consumer prices rose 2.7% year-over-year in June, suggesting that President Trump's tariffs are starting to be felt across the economy.
Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call Transcript May 12, 2025Neumora Therapeutics, Inc. Common Stock misses on earnings expectations.
Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q4 2024 Earnings Call Transcript
Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q4 2024 Earnings Call Transcript March 3, 2025Neumora Therapeutics, Inc. Common Stock beats earnings expectations.
Hedge Fund Resource Center Billionaire Hedge Funds
